Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nazartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 13/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CLK2 | P49760 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.41 |
| ▸ | CDK14 | O94921 | 3/20 | 0.39 |
| ▸ | CCNY | Q8ND76 | 3/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK7 | P50613 | 1/20 | 0.38 |
| ▸ | CCNH | P51946 | 1/20 | 0.38 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nazartinib SCHEMBL16767238 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16767236 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16895924 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL29470539 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL29355708 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16895927 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16767240 | 1.00 | EGFR (1.00) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16895718 | 0.97 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL16792309 | 0.97 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 | |
| Nazartinib SCHEMBL18249375 | 0.97 | EGFR (0.95) | EGFRCYP2D6CYP3A4CYP2C9CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | claimed |
| EP-4241850-A2 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | Novartis AG (CH) | 2023-09-13 | — | — | EP | claimed |
| US-20230172928-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND NAZARTINIB | NOVARTIS AG (CH) | 2023-06-08 | — | — | US | claimed |
| EP-4146217-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND NAZARTINIB | Novartis AG (CH) | 2023-03-15 | — | — | EP | claimed |
| WO-2021224867-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND NAZARTINIB | NOVARTIS AG (CH) | 2021-11-11 | — | — | WO | claimed |
| US-20210100812-A1 | Methods for Treating EGFR Mutant Cancers | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | claimed |
| US-10881664-B2 | Methods for treating EGFR mutant cancers | NOVARTIS AG (CH) | 2021-01-05 | — | — | US | claimed |
| EP-3206717-B1 | COMBINATION OF CERITINIB WITH AN EGFR INHIBITOR | NOVARTIS AG (CH) | 2020-11-25 | — | — | EP | claimed |
| EP-3174869-B1 | COMBINATION THERAPY OF A MET INHIBITOR AND AN EGFR INHIBITOR | NOVARTIS AG (CH) | 2020-08-19 | — | — | EP | claimed |
| US-20170209457-A1 | Combination Therapy | NOVARTIS AG (CH) | 2017-07-27 | — | — | US | claimed |
| EP-3191127-A1 | COMBINATION THERAPIES OF EGFR INHIBITORS | Novartis AG (CH) | 2017-07-19 | — | — | EP | claimed |
| WO-2017037579-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | claimed |
| WO-2016185333-A1 | METHODS FOR TREATING EGFR MUTANT CANCERS | NOVARTIS AG (CH) | 2016-11-24 | — | — | WO | claimed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | claimed |
| WO-2016055916-A1 | THERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2016-04-14 | — | — | WO | claimed |
| WO-2016040882-A1 | COMBINATION THERAPIES OF EGFR INHIBITORS | NOVARTIS AG (CH) | 2016-03-17 | — | — | WO | claimed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | claimed |
| WO-2015085482-A1 | EGFR INHIBITOR FORMS | NOVARTIS AG (CH) | 2015-06-18 | — | — | WO | claimed |
| WO-2015083059-A1 | FORMS OF THE EGFR INHIBITOR | NOVARTIS AG (CH) | 2015-06-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398115-A1 | MDM2 INHIBITORS AND COMBINATIONS THEREOF | TP53, MDM2, BCL2 | EGFR 261/4885CYP2D6 1825/4885CYP3A4 3133/4885 |
| US-20170209457-A1 | Combination Therapy | MET, EGFR, RET | EGFR 2/4885CYP2D6 4566/4885CYP3A4 4707/4885 |
| US-10881664-B2 | Methods for treating EGFR mutant cancers | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4835/4885CYP3A4 4824/4885 |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4785/4885CYP3A4 4848/4885 |
| US-20210100812-A1 | Methods for Treating EGFR Mutant Cancers | EGFR, ERBB2, ERBB3 | EGFR 1/4885CYP2D6 4843/4885CYP3A4 4835/4885 |
| US-20230172928-A1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND NAZARTINIB | PTPN5, PTPN1, PTPN13 | EGFR 14/4885CYP2D6 2609/4885CYP3A4 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.